From natural products to Alzheimer experimental therapeutics, eserine based drugs as symptomatic and disease altering agents

Progress in Nutrition

Volumn 12, Issue 1, 2010, Pages 58-63

  Greig, Nigel H ^a   Becker, R E ^a   Yu, Q ^a   Holloway, H W ^a   Tweedie, D ^a,b   Luo, W ^a   Utsuki, T ^c   Ingram, D K ^c   Maccecchini, M L ^d   Rogers, J T ^e   Sambamurti, K ^f   Lahiri, D K ^g  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b MEDSTAR RESEARCH INSTITUTE   (United States)

^c PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^d QR Pharma Inc   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^g INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Eserine; Physostigmine

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BISNORCYMSERINE; CHOLINESTERASE; CYMSERINE; PHENETHYLCYMSERINE; PHENSERINE; PHYSOSTIGMINE; PLACEBO; UNCLASSIFIED DRUG;

AGING; ALZHEIMER DISEASE; ARTICLE; CHOLINERGIC SYSTEM; DRUG BLOOD LEVEL; DRUG HALF LIFE; ENZYME INHIBITION; HUMAN; NONHUMAN; PHARMACODYNAMICS;

EID: 77953878002     PISSN: 11298723     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Newman DJ, Cragg GM, Snader KM. Natural products as sources of new drugs over the period 1981-2002. J Nat Prod. 2003; 66: 1022-37.
2. Greig NH, Pei XF, Soncrant TT, Ingram, DK, Brossi A. Phenserine and ring-C hetero-analogues: drug candidates for the treatment of Alzheimer's disease. Med. Chem. Rev. 1995; 15: 3-31.
3. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics, Science 2002; 297: 353-6.
4. Sambamurti K, Greig NH, Lahiri DK. Advances in the cellular and molecular biology of the beta-amyloid protein in Alzheimer's disease. Neuromolecular Med 2002; 1: 1-31. (Pubitemid 37021521)
5. Lacor PN. Synaptic targeting by Alzheimer's-related amyloid beta oligomers. J Neurosci 2004: 24: 10191-200.
6. Lesne S, Koh MT, Kotilinek L, et al. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 2006; 440: 352-7.
7. Schliebs R. Basal forebrain cholinergic dysfunction in Alzheimer's disease-interrelationship with beta-amyloid, inflammation and neurotrophin signaling. Neurochem Res 2005; 30: 895-908. (Pubitemid 41413946)
8. Bierer LM, Haroutunian V, Gabriel S, et al. Neurochemical correlates of dementia severity in Alzheimer's disease: relative importance of the cholinergic deficits. J Neurochem 1995; 64: 749-60.
9. Reale M, Greig NH, Kamal MA. Peripheral chemo-cytokine profiles in Alzheimer's and Parkinson's diseases. Mini Rev Med Chem 2009; 9: 1229-41.
10. Soreq H, Seidman S. Acetylcholinesterase - New roles for an old actor. Nat Rev Neurosci 2001; 2: 294-302. (Pubitemid 33673070)
11. Darvesh S, Hopkins D, Geula C. Neurobiology of butyrylcholinesterase. Nat Rev Neurosci 2003; 4: 131-8.
12. Diamant S, Podoly E, Friedler A, Ligumsky H, Livnah O, Soreq H. Butyrylcholinesterase attenuates amyloid fibril formation in vitro. PNAS 2006; 103: 8628-33.
13. Greig NH, Lahiri DK, Sambamurti K. Butyrylcholinesterase: an important new target in Alzheimer's disease therapy. International Psychogeriatrics 2002; 14: 77-9
14. Greig NH, Sambamurti K, Yu QS, Brossi A, Bruinsma GB, Lahiri DK. An overview of phenserine tartrate, a novel acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Curr Alzheimer Res. 2005; 2: 281-90.
15. Klein J. Phenserine. Expert Opin Investig Drugs. 2007; 16: 1087-97.
16. Kadir A, Andreasen N, Almkvist O, et al. Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease. Ann Neurol 2008; 63: 621-31.
17. Greig NH, Utsuki T, Ingram DK, et al., Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent. PNAS 2005; 102: 17213-8.
18. Shaw KT, Utsuki T, Rogers J, et al. Phenserine regulates translation of beta -amyloid precursor protein mRNA by a putative interleukin-1 responsive element, a target for drug development. PNAS 2001; 98: 7605-10.
19. Cahill CM, Lahiri DK, Huang X, Rogers JT. Amyloid precursor protein and alpha synuclein translation, implications for iron and inflammation in neurodegenerative diseases. Biochim Biophys Acta 2009; 1790: 615-28.
20. Lahiri DK, Chen D, Maloney B, et al. The experimental Alzheimer's disease drug posiphen [(+)-phenserine) lowers amyloid-beta peptide levels in cell culture and mice. J Pharmacol Exp Ther 2007; 320: 386-96. (Pubitemid 46025753)